Back to top
more

Catalent (CTLT)

(Real Time Quote from BATS)

$58.50 USD

58.50
284,255

+0.10 (0.17%)

Updated Jul 25, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Catalent (CTLT)

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent (CTLT) Expands Facility Capabilities in Shanghai

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day

CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.

Brian Bolan headshot

Bear Of The Day: Catalent (CTLT)

Earnings estimates have slipped for this stock following the most recent earnings miss.

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 14th

AHEXY, BLWYY, and CTLT have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2022.

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Why Is Catalent (CTLT) Down 18.5% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.